GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mayne Pharma Group Ltd (OTCPK:MYPHY) » Definitions » 3-Year Book Growth Rate

Mayne Pharma Group (Mayne Pharma Group) 3-Year Book Growth Rate : -14.90% (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Mayne Pharma Group 3-Year Book Growth Rate?

Mayne Pharma Group's Book Value per Share for the quarter that ended in Dec. 2023 was $43.69.

During the past 12 months, Mayne Pharma Group's average Book Value per Share Growth Rate was -25.50% per year. During the past 3 years, the average Book Value per Share Growth Rate was -14.90% per year. During the past 5 years, the average Book Value per Share Growth Rate was -15.80% per year. During the past 10 years, the average Book Value per Share Growth Rate was 4.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Mayne Pharma Group was 51.10% per year. The lowest was -20.50% per year. And the median was 14.65% per year.


Competitive Comparison of Mayne Pharma Group's 3-Year Book Growth Rate

For the Drug Manufacturers - General subindustry, Mayne Pharma Group's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mayne Pharma Group's 3-Year Book Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mayne Pharma Group's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Mayne Pharma Group's 3-Year Book Growth Rate falls into.



Mayne Pharma Group 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.


Mayne Pharma Group  (OTCPK:MYPHY) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.


Mayne Pharma Group 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Mayne Pharma Group's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Mayne Pharma Group (Mayne Pharma Group) Business Description

Traded in Other Exchanges
Address
1538 Main North Road, Salisbury South, Salisbury, SA, AUS, 5106
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Branded Products (BPD) and Portfolio Products Division (PPD). The Portfolio Products Division distributes dermatology products (branded and generic) in the US on a portfolio basis, The Branded Products Division distributes branded women's health products in the US. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.